ストックスクリーナーアプリを入手
14.54
19.32%
2.355
アフターアワーズ：
14.53
-0.015
-0.10%
4 D Molecular Therapeutics Inc (FDMT) 最新ニュース
4D Molecular Therapeutics (NASDAQ: FDMT) legal chief sells 3,270 shares - Stock Titan
Scott Bizily plans new 4D Molecular (NASDAQ: FDMT) sale after 10b5-1 stock trades - Stock Titan
4DMT Announces New Employment Inducement Grants - The Manila Times
H.C. Wainwright reiterates Buy on 4D Molecular stock, $36 target By Investing.com - Investing.com Nigeria
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
4D Molecular Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Is 4D Molecular Therapeutics Inc (FDMT) Undervalued After Q2 Ear - GuruFocus
4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results - MarketBeat
FDMT (NASDAQ: FDMT) stockholder schedules 1,635-share sale after option exercise - Stock Titan
4D Molecular Therapeutics (FDMT) posts $141.7M first-half 2026 net loss - Stock Titan
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
4D Molecular Therapeutics Inc (FDMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dimensional Fund Advisors LP Purchases 227,982 Shares of 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
4D Molecular Therapeutics (FDMT) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
4D Molecular Therapeutics Inc (FDMT) Stock News Today - TradingKey
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a shareEarnings Preview - TradingView
4D Molecular Therapeutics Inc (FDMT) Stock Price, Trades & News - GuruFocus
4D Molecular Therapeutics, Inc. (FDMT) insider sells 26,842 shares under plan - Stock Titan
Ken Fisher's 4D Molecular Therapeutics Inc(FDMT) Holding History - GuruFocus
4D Molecular Therapeutics (FDMT) Insider David Kirn Sells 12,415 Shares - GuruFocus
FDMT (FDMT) insider plans 26,842-share Class A sale after sizable prior trades - Stock Titan
David Kirn Sells 12,415 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock - MarketBeat
4D Molecular Therapeutics (FDMT) CEO sells 12,415 shares via 10b5-1 plan - Stock Titan
Enterprise value to revenue forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView
Form 144 4D Molecular Therapeutics For: 4 August By Investing.com - Investing.com Nigeria
FDMT (FDMT) investor David Kirn plans Rule 144 sale of 12,415 shares - Stock Titan
Janus Henderson Group PLC Acquires 611,276 Shares of 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
4D Molecular Therapeutics, Inc. Revenue Breakdown – NASDAQ:FDMT - TradingView
Exome Asset Management LLC Purchases New Position in 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
4D Molecular Therapeutics Inc (FDMT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
4D Molecular Therapeutics Inc (FDMT) Income Statement - tradingkey.com
4D Molecular Therapeutics Inc (FDMT) Valuation: PE, PB & Fair Value Analysis - TradingKey
FDMT|4D Molecular Therapeutics Inc|Price:10.380|Chg%:+0.310 - TradingKey
4D Molecular Therapeutics Inc (FDMT) Balance Sheet - TradingKey
4D Molecular Therapeutics Inc (FDMT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
4D Molecular Therapeutics Inc (FDMT) Institutional Confidence - TradingKey
4D Molecular Therapeutics Inc (FDMT) Cash Flow - TradingKey
4D Molecular Therapeutics Inc - TradingKey
4D Molecular Therapeutics Inc (FDMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
FDMT|4D Molecular Therapeutics Inc|Price:10.070|Chg%:-0.310 - TradingKey
4D Molecular releases phase 2 data for wet AMD asset 4D-150 - MSN
4D Molecular's one-shot eye therapy delivers two-year win - MSN
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Tempus AI, Inc. Class A (TEM) - The Globe and Mail
4D Molecular Therapeutics (FDMT) Reports Positive Phase 2 Results for AMD Treatment - GuruFocus
4D Molecular Therapeutics Posts Strong 4D-150 Trial Results - The Globe and Mail
4D Molecular Therapeutics reports positive 2-year Phase 2b PRISM data for 4D-150 in wet AMD - Bitget
symbol__ Stock Quote Price and Forecast - CNN
4D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion Opportunity (FDMT) - Seeking Alpha
Why Is 4D Molecular Therapeutics Stock Gaining Monday?4D Molecular Therapeutics (NASDAQ:FDMT) - Benzinga
4D Molecular Therapeutics Reports Positive 2-Year Phase 2b Results for 4D-150 in Wet AMD, Shows Reduced Treatment Burden and Strong Safety Profile 5678 – Minichart - Minichart
4D Molecular Therapeutics (Nasdaq: FDMT) posts positive 2-year wet AMD data - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Receives "Buy" Rating from HC Wainwright - MarketBeat
4D Molecular Therapeutics (FDMT) TD Cowen 46th Annual Health Care Conference summary - Quartr
4D Molecular Therapeutics (FDMT) Morgan Stanley 23rd Annual Global Healthcare Conference summary - Quartr
4D Molecular Therapeutics Announces Positive Two-Year PRISM Phase 2b Data for 4D-150 in Wet AMD - Quiver Quantitative
A single 4D-150 dose cut wet AMD treatment burden 78% - Stock Titan
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):